VERTEX PHARMACEUTICALS INC / MA 4
4 · VERTEX PHARMACEUTICALS INC / MA · Filed Jan 6, 2017
Insider Transaction Report
Form 4
BOGER JOSHUA S
DirectorCEO
Transactions
- Exercise/Conversion
Common Stock
2017-01-04$36.30/sh+6,500$235,950→ 274,725 total - Sale
Common Stock
2017-01-04$75.64/sh−200$15,128→ 274,525 total - Sale
Common Stock
2017-01-04$77.69/sh−1,900$147,611→ 268,225 total - Exercise/Conversion
Stock Option (Right to Buy)
2017-01-04−6,500→ 8,000 totalExercise: $36.30Exp: 2017-01-23→ Common Stock (6,500 underlying) - Sale
Common Stock
2017-01-04$76.95/sh−4,400$338,580→ 270,125 total
Holdings
- 78,200(indirect: By Trust)
Common Stock
- 13,286(indirect: By 401(k))
Common Stock
Footnotes (6)
- [F1]Transaction made pursuant to Dr. Boger's company approved trading plan under Rule 10b5-1.
- [F2]Dr. Boger undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
- [F3]Open market sales reported on this line occurred at a weighted average price of $75.64 (range $75.22 to $76.06).
- [F4]Open market sales reported on this line occurred at a weighted average price of $76.95 (range $76.35 to $77.28).
- [F5]Open market sales reported on this line occurred at a weighted average price of $77.69 (range $77.41 to $78.04).
- [F6]Fully vested.